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Abstract
Non-endemic Burkitt lymphoma (BL) is a rare germinal center B-cell derived malignancy with the 
genetic hallmark of MYC gene translocation and with rapid, tumor growth as a distinct clinical 
feature. To investigate treatment outcomes, loss of lifetime, and relapse risk in adult BL patients 
treated with intensive immunochemotherapy, retrospective clinic-based and population-based 
lymphoma registries from six countries were used to identify 264 real-world patients. The median 
age was 47 years and the majority had advanced stage disease and elevated LDH. Treatment 
protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-
BFM/GMALL (25%), and other (2%) leading to overall response rate of 89%. The 2-year overall 
survival and event-free survival were 84% and 80%, respectively. For patients in complete 
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12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients 
was 0.4 (95%CI:-0.7-2) months. In conclusion, real-world outcomes of adult BL are excellent 
following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life 
expectancy similar to that of a general population, which is important information for developing 
meaningful follow-up strategies with increased focus on survivorship and less focus on routine 
disease surveillance. 
Introduction
Non-endemic Burkitt lymphoma (BL) is a rare germinal center B-cell derived malignancy and 
among the most aggressive types of non-Hodgkin lymphomas (NHL) (Swerdlow et al, 2017). The 
majority of BL patients are diagnosed with advanced stage disease and have extensive extranodal 
involvement, which can lead to oncologic emergencies such as tumor compression of vital organs 
and/or life-threatening tumor lysis (Molyneux et al, 2012; Dunleavy et al, 2013; Castillo et al, 
2013). However, BL is highly sensitive to chemotherapy and rapid reduction in tumor volume is 
typically seen within days after commencing treatment (Blum et al, 2004). In particular, the 
outcomes for adult BL have improved dramatically after adopting the intensive multidrug 
chemotherapy protocols used in pediatric BL or acute lymphoblastic leukemia (ALL) instead of the 
more conventional NHL regimens such as cyclophosphamide, doxorubicin, vincristine, and 
prednisolone (CHOP) (Magrath et al, 1984, 1996; Diviné et al, 2005; Dave et al, 2006; Wästerlid et 
al, 2013; Smeland et al, 2004). Inclusion of rituximab in first-line therapy has led to further survival 
improvements, similarly to other aggressive B-cell lymphomas (Ribrag et al, 2016; Rizzieri et al, 
2014; Barnes et al, 2011; Hoelzer et al, 2014; Thomas et al, 2006; Corazzelli et al, 2012; Wästerlid 
et al, 2013). However, intensive multidrug chemotherapy protocols are associated with risk of life-















This article is protected by copyright. All rights reserved
Barnes et al, 2011; Hoelzer et al, 2014; Ribrag et al, 2016). Additionally, the favorable results seen 
in clinical trials using such treatment protocols do not necessarily apply to the broad population of 
patients in the routine clinical setting, who may be older, frailer, or have urgent need for treatment 
excluding them from trial inclusion (Maurer et al, 2018). 
In the present international study, BL outcomes following treatment with intensive 
immunochemotherapy regimens are reported together with dynamic survival estimates and relapse 
risks based on population and clinic-based registries.
Patients and methods
This retrospective study included patients from clinic-based and population-based lymphoma 
registries in Australia (Sir Charles Gairdner Hospital [Perth]), Canada (BC Cancer Lymphoid 
Cancer and Leukemia/BMT Program Databases [Vancouver]), Denmark (the Danish Lymphoma 
Registry [LYFO]), Norway (Health Region South East, Oslo University Hospital), Sweden (the 
Swedish Lymphoma Registry [SLR]), and the USA (Mayo Clinic [Rochester, Minnesota] and 
University of Iowa [Iowa City, Iowa]). The registries are described in detail in the Supplementary 
text. Patient information was retrieved from the registries with additional data abstraction from 
medical records as necessary. The surveyed time period was 2004-2017, with local differences 
depending on the structure of the registries. 
The study relied on the BL diagnosis made by the treating physicians based on all available clinical 
information and pathology results. As part of this study and to ensure that the BL diagnosis was 
made in accordance with central diagnostic criteria used today (Swerdlow et al, 2017). local 
investigators performed additional retrospective reviews of pathology reports to document that the 
BL diagnosis was made based on the presence of; 1) medium-sized monotonous lymphocytes with 
diffuse growth pattern, 2) high proliferation rate (KI-67 ≥90% if KI-67 had been performed), 3) 
typical germinal center B-cell markers, such as CD20+, CD10+, and Bcl6+, on 
immunohistochemistry, and 4) fluorescence in-situ hybridization (FISH) detected MYC 
translocation (Swerdlow et al, 2008). Patients without FISH detected MYC translocation were 
excluded from the present study, to minimize inclusion of patients that would have been classified 
as unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell 
lymphoma and BL according to the 2008 WHO classification (Swerdlow et al, 2008). However, we 
acknowledge that BL may still be diagnosed in the absence of MYC rearrangements if other 
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for the new provisional BL category with chromosome 11q aberrations without MYC translocation 
were not included (Swerdlow et al, 2017). 
Adult patients (aged ≥18 years) treated with rituximab-containing dose-intense chemotherapy 
protocols (mostly but not limited to DA-EPOCH-R [dose-adjusted etoposide, prednisone, 
vincristine, cyclophosphamide, and doxorubicin], R-hyper-CVAD [hyper-fractionated 
cyclophosphamide, vincristine, doxorubicin, dexamethasone, intrathecal (IT) methotrexate, and IT 
cytarabine alternated with high dose (HD) methotrexate, and cytarabine], R-CODOX-M/IVAC 
[cyclophosphamide, vincristine, doxorubicin, IT cytarabine, HD methotrexate, IT methotrexate / 
etoposide, ifosfamide, cytarabine, IT methotrexate], and the R-BFM/GMALL protocol [prednisone, 
cyclophosphamide, HD methotrexate, dexamethasone, ifosfamide, etoposide, , doxorubicin, 
vincristine/vindesine, cytarabine,  IT methotrexate, IT cytarabine, and IT dexamethasone]) were 
included in the study. Patients were grouped according to the first intensive treatment they received 
in an intention-to-treat analysis, but a single cycle of CHOP-like therapy was allowed before 
initiation of intensive treatment, as this strategy is frequently used to achieve immediate disease 
control pending final diagnosis. As a rule, disease staging included full body computed tomography 
(CT) or fluorodeoxyglucose (FDG)- positron emissions tomography (PET)/CT-based imaging, bone 
marrow biopsy and cytological evaluation of cerebrospinal fluid as part of first IT treatment in 
patients receiving therapies that included this or if CNS involvement was suspected. Clinical tumor 
lysis was classified using established criteria (Howard et al, 2011).
Response evaluations were performed in accordance with relevant response criteria, depending on 
the use of CT or FDG-PET/CT-based imaging (Cheson et al, 1999, 2007, 2014). As a rule, bone 
marrow biopsy was repeated as a part of the post-therapeutic response assessment in cases with pre-
therapeutic bone marrow involvement.
A subset of the patients included in the present study have been reported in previously published 
studies, but outcomes of different treatment strategies, documentation of MYC translocation, 
confirmation of response by reviewing medical files, or reporting of novel outcomes measures such 
as dynamic relapse risks and conditional survival estimates were not part of these studies (Wästerlid 
et al, 2013; Zhu et al, 2018). The study was conducted in accordance with national and local 
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Overall survival (OS) was defined as the time from diagnosis until death from any cause or 
censoring of patients still alive at end of follow-up, whereas event-free survival (EFS) was defined 
as the time from diagnosis until unplanned re-treatment, progression/relapse, death or censoring at 
end of follow-up. Survival probabilities were estimated using the Kaplan-Meier estimator (Kaplan 
& Meier, 1958). The treatment groups were compared using an inverse probability of treatment 
weighting (IPTW) approach to adjust for imbalances between the groups (see Supplementary text) 
(Austin & Stuart, 2015). Because IPTW requires that all treatment groups are represented at every 
combination of the observed confounders, the imbalances were only adjusted for age as a 
continuous variable, gender, and stage (I-II vs. III-IV) (Westreich & Cole, 2010). In a sensitivity 
analysis, we additionally adjusted for performance status (0-1 vs >1), number of extranodal sites, 
lactate dehydrogenase (LDH) level (elevated vs normal), and the presence of B symptoms. We used 
the Benjamini-Hochberg method to adjust for multiple testing when comparing the treatment 
groups (Benjamini & Hochberg, 1995). Cause-specific cumulative incidences of death were 
estimated using the Aalen-Johansen estimator (Martinussen & Scheike, 2006). The 5-year restricted 
loss of lifetime (RLOL) was calculated as the area between the BL Kaplan-Meier curve and the 
general population survival curve obtained using the Ederer I method (Ederer et al, 1961) and 
country-specific life tables retrieved from the Human Mortality Database stratified on age, gender, 
and calendar year (University of California Berkeley & Max Planck Institute for Demographic 
Research). 
For patients reaching complete remission (CR)/CR unconfirmed (CRu), the post-remission overall 
survival (pOS), cumulative incidence of relapse, and 5-year RLOL estimates were computed with 
follow-up measured from the time of response evaluation. The pOS, relapse risk, and the 5-year 
RLOL were also computed for the subset of patients event-free at 6 (pEFS6) and 12 (pEFS12) 
months post-CR with follow-up measured from the milestones. 
Prognostic factors were examined using univariable and multivariable Cox proportional hazards 
models for EFS and a score test statistic was used to test for proportional hazards (Grambsch & 
Therneau, 1994). All analyses were conducted in the statistical programming language R. 
Results
Patients and Treatment
A total of 264 patients from 6 different countries (Australia, 18; Canada, 73; Denmark, 61; Norway, 
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study (Figure S1). Baseline clinicopathological characteristics of the included patients are shown in 
Table 1 (see Table S1 for characteristics stratified on country). The most frequently used intensive 
chemotherapy protocol was R-CODOX-M/IVAC (47% of the patients). R-BFM/GMALL and R-
hyper-CVAD were used in 66 (25%) and 41 (16%) of the patients, respectively, while 28 (11%) 
received DA-EPOCH-R. Treatment de-escalation was chosen for 11 (4%) patients and 9 (3%) 
changed to another intensive chemotherapy regimen (Figure S1). Thirteen patients received 
consolidative bone marrow transplant (BMT) after treatment with R-CODOX-M/IVAC. Country-
specific distributions of first-line therapy are provided in Table S2 and clinicopathologic differences 
between treatment groups are shown in Table S3. Among the 178 (67%) patients for whom data on 
clinical tumor lysis syndrome were available, 32 (18%) patients developed clinical tumor lysis upon 
initiation of therapy. All tumor lysis patients presented with high-risk disease including advanced 
stage and elevated LDH. 
The overall response rate was 89% (85% CR/CRu and 4% partial remission [PR]), with 108 
patients (44%) response assessed using FDG-PET technology. The median follow-up for the entire 
patient cohort computed by the reverse Kaplan-Meier method was 54 months (95% CI, 50-62) and 
the estimated 2-year OS and EFS were 84% (95% CI, 79%-88%) and 80% (95% CI, 75%-85%), 
respectively (Figure 1). The 2-year OS of patients <40, 40-59, and ≥60 years was 92% (95% CI, 
87%-97%), 83% (95% CI, 75%-91%), and 72% (95% CI, 61%-83%), respectively (Figure 1). In 
adolescents and young adults (AYAs, <40 years of age), particularly high OS and EFS was 
observed among patients aged 18-21 (2-year OS and EFS, 100%) and 22-30 (2-year OS and EFS, 
98% and 93%, respectively, Figure S2). Clinical factors associated with unfavorable EFS and OS in 
univariable analyses were age and elevated LDH. Both retained significance in multivariable 
analyses (Table S4 and S5). The 2-year EFS for patients with stage III-IV disease and elevated 
LDH was 73% (95% CI, 66%-80%). Among the subset of patients with CNS involvement at 
diagnosis (n=21), the 2-year OS and EFS were 80% (95% CI, 63%-98%) and 70% (95% CI, 50%-
90%), respectively. 
Outcomes after response evaluation
For patients in CR/CRu following intensive immunochemotherapy with available date of response 
assessment (n=223), the 2-year cumulative relapse risk from response assessment was 6% (95% CI, 
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relapse risk of 3% (95% CI, 0%-5%) and 0.6% (95% CI, 0%-2%), respectively (Figure 2). The 
corresponding 2-year pOS estimates were 92% (95% CI, 89%-96%), 96% (95% CI, 93%-99%), and 
98% (95% CI, 95%-100%) from response assessment, pEFS6, and pEFS12, respectively (Figure 
S3). The 5-year RLOL was 4 months (95% CI, 2-6) from the time of response assessment, while 
patients reaching pEFS6 and pEFS12 had a 5-year RLOL of 2 (95% CI, 0.2-3) and 0.4 (95% CI, -
0.7-2) months, respectively. 
RLOL estimates stratified according to baseline clinicopathologic features are reported in Figure 3. 
From the time of response assessment, low-risk features such as limited stage, performance status 
0-1, age <40, and normal LDH values were associated with lower RLOL. However, the impact of 
high-risk features on RLOL diminished as time in CR/CRu elapsed. This effect was especially 
pronounced for performance status. The 2-year OS from response evaluation in patients with 
progressive disease (n=13) was 8% (95% CI, 0%-22%, Figure 4A). Patients who relapsed after 
achieving initial CR/CRu (n=14) had dismal outcomes with 2-year post-relapse OS of 14% (95% 
CI, 0%-33%, Figure 4B).
Outcomes according to intensive immunochemotherapy protocols
A global log-rank test did not detect any significant OS difference between the treatment groups 
(P=0.2, Figure 5A). Survival curves adjusted for age, gender, and stage are provided in Figure 5B. 
Although we found significantly improved OS among patients treated with R-CODOX-M/IVAC 
compared to R-hyper-CVAD (P=0.04) after adjusting for age, gender, and stage, these were not 
significantly different after adjusting for multiple comparisons (P=0.24). No other OS differences 
were observed between the treatment groups (Table S6). This result was similar for EFS (Figure S4 
and Table S6) and a sensitivity analysis also adjusting for performance status, extranodal sites, B 
symptoms, and LDH did not change the conclusion (Figure S5). The 28 patients treated with DA-
EPOCH-R had 2-year OS and EFS of 77% (95% CI, 61%-93%, Figure 5A) and 74% (95% CI, 
57%-91%, Figure S2A), respectively. 
Discussion
In the present international study, we investigated real-world outcomes of newly diagnosed BL 
patients treated with intensive chemotherapy regimens and rituximab. We demonstrated a high 
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patients with CNS involvement at diagnosis. The relapse risk was minimal after 12 months in 
remission, an important finding when it comes to developing rational disease surveillance strategies 
and survivorship care plans. 
BL is rare in the Western World with an estimated incidence rate in 2008 of 2.36 and 5.95 per 
1,000,000 person-years for females and males, respectively (Costa et al, 2013). This, combined 
with the aggressive clinical presentation and urgent need for treatment, make large randomized 
trials challenging. The use of intensive multidrug chemotherapy regimens inspired by those used for 
pediatric ALL are effective in BL, but toxicity limits their application to adult patients with BL 
(Costa et al, 2013). However, Margrath et al. reported comparable efficacy and toxicity for children 
and adults (aged 18-59) in a study of 41 BL patients treated with CODOX-M/IVAC (Magrath et al, 
1996). Other single arm phase II studies and multicenter retrospective studies of ALL(-like) 
treatment regimens have confirmed the efficacy of this strategy in adults (Soussain et al, 1995; 
Thomas et al, 1999; Hoelzer et al, 1996; Diviné et al, 2005; Mead et al, 2002). Common toxicities 
include myelosuppression and mucositis and toxic deaths were reported in most studies (Diviné et 
al, 2005; Soussain et al, 1995; Thomas et al, 1999; Hoelzer et al, 1996; Mead et al, 2002). In the 
present study, outcomes were excellent despite a median age of 47 years, and consistent with 
previous studies, age was significantly associated with OS and EFS (Thomas et al, 1999; Diviné et 
al, 2005; Zhu et al, 2018). The AYA patient population had excellent outcomes with 2-year OS of 
92%. Of note, consolidative BMT was given to 13 patients treated with R-CODOX-M/IVAC, but 
this did likely not impact outcomes (Zhu et al, 2018).
Less intensive treatments such as CHOP or CHOEP are associated with poor outcomes in BL 
(Smeland et al, 2004; Wästerlid et al, 2013). In a retrospective Norwegian cohort study of 49 BL 
patients, investigators reported poorer outcomes among patients treated with CHOP and 
methotrexate, relative to BFM (5-year progression-free survival [PFS] was 31% and 74%, 
respectively) (Smeland et al, 2004), and these results were confirmed in a Danish-Swedish 
population-based study of patients diagnosed in the period 2000-2009 (Wästerlid et al, 2013). 
Several groups have reported modest improvements from the addition of rituximab to first-line 
treatment of BL in phase II studies (Evens et al, 2013; Intermesoli et al, 2013; Hoelzer et al, 2014; 
Thomas et al, 2006). The benefit of rituximab was confirmed in the only randomized trial of adult 
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2016). Similar outcomes (2-year EFS, 80%) were observed in the present cohort of real-world 
patients suggesting that the clinical trial result can be extrapolated to daily clinical practice.
DA-EPOCH-R is less dose-intensive than typical ALL(-like) regimens, but still highly efficacious 
for BL in two recent phase II trials of 30 and 113 patients with or without HIV (Dunleavy et al, 
2013; Roschewski et al, 2017). Toxicity was manageable with fever and neutropenia requiring 
hospital admissions in 26/116 treatment cycles and with few cases of mucositis. Despite the 
inclusion of patients >85 years of age, the 2-year OS of HIV-negative patients (n=19) was 100% in 
the pivotal phase 2 study of DA-EPOCH in BL, while patients in the NCI9177 study had a 2-year 
OS of 86% with DA-EPOCH using an interim PET adapted treatment strategy (Dunleavy et al, 
2013; Roschewski et al, 2017). Patients treated with DA-EPOCH-R in our study (n=28) had more 
high-risk features than the patients enrolled in the study by Dunleavy et al. (Table S7). These 
differences may explain why the 2-year OS and EFS of 77% (95% CI 61%-93%) and 74% (95% CI 
57%-91%) in the present study were lower than the 100% OS and 95% PFS reported by Dunleavy 
et al. (Dunleavy et al, 2013). 
The event-free survival at 24 months end-point and others like this provide an intuitive framework 
for patient counselling and may also serve as surrogate end-points in clinical trials (Maurer et al, 
2014; Shi et al, 2018). In the present study, we demonstrated normalization of survival and a 
negligible relapse risk for patients with BL remaining in remission 12 months after completing 
intensive immunochemotherapy. Although late disease relapse was rare in this study, the 
occurrence of late toxicity remains a concern and provides potential rationale for changing focus 
from disease surveillance and cost-ineffective screening for asymptomatic relapse to improving 
survivorship in these heavily treated patients.
The main strength of the present multicenter study was the inclusion of a large number of real-
world adult BL patients ensuring that our results are generalizable to a broad population of patients. 
We also used novel, patient-centered outcome measures to facilitate more meaningful patient 
counselling in clinical practice. However, the study also has important limitations inherent to the 
observational design. Therapies were selected at the discretion of the attending physician, and 
treatment-specific outcome differences can be confounded by selection bias. IPTW used in the 
present study may overcome this to some extent, but unknown sources of bias and limited number 
of patients in each subgroup limits the strength of our conclusions. No data on dose intensity was 
collected, but it is likely that some patients, in particular patients ≥60 years, received dose-modified 
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outcomes when compared to younger adults in most studies (Intermesoli et al, 2013; Hoelzer et al, 
2014; Lacasce et al, 2004; Corazzelli et al, 2012; Thomas et al, 2006; Ribrag et al, 2016; Mead et 
al, 2008; Zhu et al, 2018). Consistently, in the current study patients ≥60 years of age had 
significantly greater loss of lifetime. HIV or immunodeficiency status was not consistently 
available, but sites contributing to the study were from low endemic HIV areas making sporadic BL 
the main driver of our results. Furthermore, highly active antiretroviral therapy was available during 
the surveyed time period, and this has increased survival of HIV-associated BL to that of sporadic 
BL (Intermesoli et al, 2013; Ribera et al, 2013; Rodrigo et al, 2012; Oriol et al, 2008; Dunleavy et 
al, 2013; Barnes et al, 2011; Zhu et al, 2018). 
Based on this study, we conclude that intensive multidrug immunochemotherapy protocols are 
highly effective for achieving durable remissions in adult BL patients. Early normalization of 
survival and a negligible relapse risk for patients in remission for 12 months can reassure BL 
patients and their families as well as guide appropriate use of limited health care resources for 
disease surveillance. However, the dismal outcomes among patients who are refractory or relapse 
highlight an unmet medical need in this subgroup. Future research efforts should focus on inclusion 
of novel agents and/or further refined dynamic risk adapted treatment strategies based on early 
therapy response to reduce treatment toxicity without compromising efficacy.
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Table 1: Demographics, treatment information, and final response evaluation for 263 Burkitt 
lymphoma patients treated with intensive immunochemotherapy. 
All patients (n = 264)
Median age (range) 47(18-81) 
Male patients 200(76) 
Ann Arbor stage III-IV, n(%) 205(78) 
ECOG performance > 1, n(%) 91(34) 
Elevated LDH, n(%) 190(73)* 
Extranodal disease, n(%) 226(86) 
- Bone(marrow) 111(42) 
- Central nervous system 21(8) 
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Country, n(%) 
- Australia 18(7) 
- British Columbia 73(28) 
- Denmark 61(23) 
- Norway 41(16) 
- Sweden 56(21) 
- USA 15(6) 
Primary treatment, n(%) 
- R-CODOX-M/IVAC 124(47) 
- R-Hyper-CVAD 41(16) 
- R-DA-EPOCH 28(11) 
- R-BFM/GMALL 66(25) 
- Other 5(2) 
PET or PET/CT-based response, n(%) 108(44)* 
Response evaluation, n(%) 
- CR/CRu 224(85) 
- PR 10(4) 
- Less than PR 30(11) 
* Missing information on a subset of the patients
R-CODOX-M/IVAC cyclophosphamide, vincristine, doxorubicin, IT cytarabine, HD methotrexate, IT methotrexate / 
etoposide, ifosfamide, cytarabine, IT methotrexate plus rituximab
R-hyper-CVAD: hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, IT methotrexate, and 
IT cytarabine alternated with high dose (HD) methotrexate, and cytarabine plus rituximab
DA-EPOCH-R: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab
R-BFM/GMALL: prednisone, cyclophosphamide, HD methotrexate, dexamethasone, ifosfamide, etoposide, 
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Figure 1: Overall (A) and event-free survival (B) following intensive immunochemotherapy for all 
patients and stratified according to age (<40, 40-59, and ≥60 years).
Figure 2: Cumulative incidence of relapse for patients in CR/CRu after intensive immunochemotherapy with 
time measured from response evaluation (n = 223), pEFS6 (n = 202), and pEFS12 (n = 189).
Figure 3: Five-year restricted loss of lifetime for Burkitt lymphoma patients in CR/CRu after 
intensive immunochemotherapy stratified by clinical subgroup. No females or patients between 40 
and 59 years died after achieving the pEFS12 milestone.
Figure 4: Overall survival of A) 13 BL patients responding with progressive disease to primary 
intensive immunochemotherapy and B) 14 BL patients relapsing after treatment with intensive 
immunochemotherapy.
Figure 5: A) overall survival stratified on primary treatment regimen and B) treatment-specific 
overall survival adjusted for age, gender, and stage.
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